To help facilitate choosing a therapy, Baxter has produced a Product Assessment Kit. The kit illustrates the features of the factor VIII therapies available today and also comes with the “Where does my factor come from” leaflet that explains how recombinant factor VIII is made. View the product assessment kit here.
Download and print the ADVATE patient brochure [PDF] so your patients can see why people with hemophilia A and their physicians have made ADVATE their choice more than any other therapy1*
* Based on number of units distributed in the US, beginning May 2007.
There's never been a better time for your patients to try ADVATE.
With Baxter's FREEDOM of CHOICE trial program, your patient can receive:
View the brochure for the new BAXJECT II, which has been completely redesigned to make mixing as easy as 1-2-3. Also view Instructions for Use [PDF]
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes and for perioperative management of patients with hemophilia A.
ADVATE is not indicated for the treatment of von Willebrand's disease.
Important Safety Information
ADVATE should be administered cautiously in patients with previous hypersensitivity to constituents of Factor VIII preparations or known sensitivity to mouse or hamster proteins.
The formation of inhibitors has been observed with all Factor VIII products, including ADVATE.
The most common related adverse reactions observed during clinical studies include: strange taste in mouth, headache, dizziness, and flushing.
ADVATE supplied with BAXJECT II Full Prescribing Information (PDF).
